Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin receptor antagonism: an ascending multiple-dose study with almorexant
Petra Hoever, Sanne Lysbet de Haas, Georg Dorffner, et al.
Journal of Psychopharmacology (2012) Vol. 26, Iss. 8, pp. 1071-1080
Closed Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Slow-wave sleep: From the cell to the clinic
Damien Léger, Eden Debellemanière, Arnaud Rabat, et al.
Sleep Medicine Reviews (2018) Vol. 41, pp. 113-132
Closed Access | Times Cited: 187
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes
Emmanuel J.M. Mignot
Neurotherapeutics (2012) Vol. 9, Iss. 4, pp. 739-752
Open Access | Times Cited: 204
Discovery and development of orexin receptor antagonists as therapeutics for insomnia
Christopher J. Winrow, John J. Renger
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 283-293
Open Access | Times Cited: 144
Physiology of the orexinergic/hypocretinergic system: a revisit in 2012
Jyrki P. Kukkonen
AJP Cell Physiology (2012) Vol. 304, Iss. 1, pp. C2-C32
Closed Access | Times Cited: 133
Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?
Daniël Hoyer, Laura H. Jacobson
Neuropeptides (2013) Vol. 47, Iss. 6, pp. 477-488
Closed Access | Times Cited: 107
Neuropeptides and Neuropeptide Receptors: Drug Targets, and Peptide and Non‐Peptide Ligands: a Tribute to Prof. Dieter Seebach
Daniël Hoyer, Tamás Bartfai
Chemistry & Biodiversity (2012) Vol. 9, Iss. 11, pp. 2367-2387
Open Access | Times Cited: 98
An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics
Kayla Janto, J. Roxanne Prichard, Snigdha Pusalavidyasagar
Journal of Clinical Sleep Medicine (2018) Vol. 14, Iss. 08, pp. 1399-1408
Open Access | Times Cited: 81
The Hypocretin/Orexin System: An Increasingly Important Role in Neuropsychiatry
Quanhui Chen, Luı́s de Lecea, Zhian Hu, et al.
Medicinal Research Reviews (2014) Vol. 35, Iss. 1, pp. 152-197
Closed Access | Times Cited: 79
Recent trends in orexin research—2010 to 2015
Christoph Boss, Catherine Roch
Bioorganic & Medicinal Chemistry Letters (2015) Vol. 25, Iss. 15, pp. 2875-2887
Closed Access | Times Cited: 74
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69
Accelerated Development of the Dual Orexin Receptor Antagonist ACT‐541468: Integration of a Microtracer in a First‐in‐Human Study
Clemens Muehlan, Jules A. A. C. Heuberger, Pierre‐Éric Juif, et al.
Clinical Pharmacology & Therapeutics (2018) Vol. 104, Iss. 5, pp. 1022-1029
Open Access | Times Cited: 59
Effects of orexin receptor antagonism on human sleep architecture: A systematic review
Jacob Clark, Maddison L. Brian, Sean P. A. Drummond, et al.
Sleep Medicine Reviews (2020) Vol. 53, pp. 101332-101332
Closed Access | Times Cited: 54
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Binding kinetics differentiates functional antagonism of orexin‐2 receptor ligands
Richard F. Mould, Jason Brown, Fiona H. Marshall, et al.
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 351-363
Open Access | Times Cited: 60
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Suvorexant for the treatment of insomnia
Laura H. Jacobson, Gabrielle E. Callander, Daniël Hoyer
Expert Review of Clinical Pharmacology (2014) Vol. 7, Iss. 6, pp. 711-730
Closed Access | Times Cited: 52
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration
Clemens Muehlan, Sander Brooks, Rob Zuiker, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 7, pp. 847-857
Closed Access | Times Cited: 49
Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis
Mengzhen Zhou, Jiyou Tang, Shasha Li, et al.
Frontiers in Human Neuroscience (2023) Vol. 16
Open Access | Times Cited: 11
Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference
Jed Black, Giora Pillar, Jan Hedner, et al.
Sleep Medicine (2017) Vol. 36, pp. 86-94
Closed Access | Times Cited: 39
The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats
Stephen R. Morairty, Alan J. Wilk, Webster U. Lincoln, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 37
Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review
Aisha S. Shariq, Joshua D. Rosenblat, Asem Alageel, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018) Vol. 92, pp. 1-7
Closed Access | Times Cited: 36
Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs
Anil Kumar, Priyanka Chanana, Supriti Choudhary
Pharmacological Reports (2015) Vol. 68, Iss. 2, pp. 231-242
Closed Access | Times Cited: 35
Orexin OX2 Receptor Antagonists as Sleep Aids
Laura H. Jacobson, Sui Chen, Sanjida Mir, et al.
Current topics in behavioral neurosciences (2016), pp. 105-136
Open Access | Times Cited: 35
Physiological Role of Orexin/Hypocretin in the Human Body in Motivated Behavior: A Comprehensive Review
Rahul Singh, Dalia Biswas
Cureus (2023)
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top